Summary & Overview
HCPCS Level II J3110: Injection, teriparatide, 10 mcg
HCPCS Level II code J3110 denotes the injection of teriparatide, 10 mcg, a parathyroid hormone analog used to stimulate bone formation in patients with osteoporosis. Nationally, this code matters because it captures administration of a specialty injectable therapy with implications for outpatient medical benefit billing, prior authorization workflows, and cost management for high-cost biologic agents. Payers such as Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare commonly adjudicate claims for this service under medical benefit rules.
Readers will find a concise overview of clinical context, coding use, and payer coverage considerations. The publication summarizes typical sites of service and common billing scenarios tied to outpatient injection administration. It highlights benchmarking metrics and policy considerations relevant to payers and providers, including authorization and documentation practices. Where specific payer policies vary, this summary notes that readers will see comparative benchmarks and policy update summaries to inform coding and billing strategy. Data not available in the input are noted where applicable.
Billing Code Overview
HCPCS Level II code J3110 describes an injection of teriparatide, 10 mcg. This code represents a single administration of the parathyroid hormone analog used primarily in the treatment of osteoporosis and to stimulate bone formation.
Service Type: Injection therapy (medication administration)
Typical Site of Service: Outpatient clinics, physician offices, and infusion or injection suites
Clinical & Coding Specifications
Clinical Context
A typical patient is a postmenopausal woman or man with osteoporosis at high risk for fracture, or a patient with glucocorticoid-induced osteoporosis, who presents to an outpatient specialty clinic (endocrinology, rheumatology, or orthopedics) for initiation or continuation of anabolic therapy. The clinician documents prior fracture history, bone mineral density T-scores, prior osteoporosis therapies, contraindications, and counseling on self-injection technique. The service includes medication administration training, review of storage and handling, dispensing or provision of a prefilled pen containing teriparatide 20 mcg/mL (billing unit J3110 represents 10 mcg of teriparatide per injection), and a focused follow-up plan for calcium and vitamin D supplementation and monitoring.
Typical workflow:
-
Patient evaluation and diagnosis confirmation with recent DXA results and fracture history.
-
Shared decision-making and informed consent for anabolic therapy.
-
Documentation of prescription and plan for self-injection; prescriber or clinician may provide initial teach-back of injection technique.
-
Pharmacy/infusion clinic dispenses or administers first dose and provides medication counseling; subsequent doses are self-administered by the patient at home and reported at follow-up visits.
-
Follow-up visits scheduled at regular intervals to assess response, side effects, adherence, and need for transition to antiresorptive therapy after completion of teriparatide course.